Bio-Thera Solutions and STADA Arzneimittel AG have agreed to extend their biosimilars alliance to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The effectiveness of the agreement is subject to shareholder approval. STADA, including its affiliates, will have exclusive rights to commercialize the biosimilar in the European Union, the UK, Switzerland and selected other countries.
Bio-Thera will maintain responsibility for development, manufacturing, and supply of the tocilizumab biosimilar to Roche's RoActemra reference brand.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.